// App-Quantinova.ai

39 : Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).

Researchers

Presenter

  • Reinhard Dummer

Principal Investigators

  • Catarina D. Campbell

  • Celeste Lebbe

  • Victoria Atkinson

  • Mario Mandal

  • Paul D. Nathan

  • Ana Arance

  • Erika Richtig

  • Naoya Yamazaki

  • Caroline Robert

  • Dirk Schadendorf

  • Hussein Abdul-Hassan Tawbi

  • Paolo Antonio Ascierto

  • Antoni Ribas

  • Keith Flaherty

  • Eduard Gasal

  • Jan C. Brase

  • Georgina V. Long

Medical Centers

  • University Hospital Zurich Skin Cancer Center, Zurich, Switzerland

  • Novartis Institutes for BioMedical Research, Inc, Cambridge, MA

  • Novartis Institutes for BioMedical Research, Inc, Cambridge, MA

  • APHP Dermatology and CIC, U976, Universite de Paris, Hopital Saint-Louis, Paris, France

  • Greenslopes Private Hospital, Gallipoli Medical Research Foundation, University of Queensland, Woolloongabba, Australia

  • Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Medical University Graz, Graz, Austria

  • National Cancer Center Hospital, Tokyo, Japan

  • Institut Gustave Roussy and Paris-Sud University, Villejuif, France

  • University Hospital Essen, University Duisburg-Essen, Essen, Germany and German Cancer Consortium, Heidelberg, Germany

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

  • University of Southern California, Los Angeles, CA

  • Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, MA

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis AG, Basel, Switzerland

  • Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia

Locations

  • Switzerland

  • United States

  • France

  • Australia

  • Italy

  • United Kingdom

  • Spain

  • Austria

  • Japan

  • Germany

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Circulating DNA

  • Tumor mutational burden

Drug/Treatment

  • PDR001

  • Dabrafenib Mesylate

  • Trametinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02967692

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved